Bionano Genomics, Inc. (BNGO) vs Marker Therapeutics, Inc. (MRKR)
A side-by-side comparison of Bionano Genomics, Inc. and Marker Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BNGO
Bionano Genomics, Inc.
$1.45HealthcareDelayed quote: Oct 6, 2026, 1:15 PM EDT
MRKR
Marker Therapeutics, Inc.
$1.03HealthcareDelayed quote: Oct 6, 2026, 1:19 PM EDT
Total return — BNGO vs MRKR
growth of $100 · dividends reinvested · last 8yBNGO -100.0% (-62.5%/yr)MRKR -98.6% (-41.2%/yr)MRKR compounded faster over this window
Log scale — wide-divergence pair
BNGO MRKR
BNGO vs MRKR: by the numbers
- •MRKR is the larger company ($17M vs $17M market cap).
- •Both run net losses; BNGO's is the smaller (-106.58% vs -706.23% net margin).
Metrics side by side
Valuation
| Metric | BNGO | MRKR |
|---|---|---|
| P/S ratio | 0.55 | 13.93 |
| P/B ratio | 0.53 | 1.41 |
Profitability
| Metric | BNGO | MRKR |
|---|---|---|
| Gross margin | 21.95% | 0.00% |
| Operating margin | -116.95% | 0.00% |
| Net margin | -106.58% | -706.23% |
| ROE | -101.76% | -71.57% |
| ROIC | -85.72% | -88.07% |
Growth (annualized)
| Metric | BNGO | MRKR |
|---|---|---|
| Revenue CAGR (5Y) | 17.97% | N/A |
| Total return CAGR (5Y) | -78.37% | -42.13% |
Frequently asked
- How have BNGO and MRKR total returns compared?
- Over the past 5 years, BNGO delivered -78.37% and MRKR delivered -42.13% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bionano Genomics ROEMarker Therapeutics ROEBionano Genomics operating marginMarker Therapeutics operating marginBionano Genomics revenue growthMarker Therapeutics revenue growthBionano Genomics free cash flowMarker Therapeutics free cash flow
Bionano Genomics & Marker Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.